MCAC Advises AMD Manufacturers To Conduct Randomized, Controlled Trials
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, CMS' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore